Hypercoagulability state in hip and knee surgery: influence of ABO antigenic system and allogenic transfusion

Transfusion Science - Tập 20 - Trang 17-20 - 1999
Teodoro Iturbe1, Rosa Cornudella1, Roberto de Miguel1, Teresa Olave1, José Antonio Moreno1, Luis Callén1, Martı́n Gutiérrez1
1Hematology and Traumatology Departments, Hospital Clı́nico Universitario, Adva San Juan Bosco 15, 50009 Zaragoza, Spain

Tài liệu tham khảo

Jack H, Sloe D, Westerholm B, Inman WHW, Vessey MP, Shapiro S, Lewis G, Worcester J. Venous Thromboembolic disease and ABO blood type. Lancet 1969;i:539–542 Talbot S, Ryrie D, Walkley EJ, Langman MJS. ABO blood groups and venous thromboembolic disease. Lancet. 1970;i:1257–1259 Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep vein thrombosis within a defined urban population. J. Intern. Med. 1992;232:155–160 Salvati EA, Lachiewicz P. Thromboembolism following total hip-replacement arthroplasty. The efficacy of dextran-warfarin in prophylaxis. J. Bone Joint Surg. 1976;58-A:921–925 Koster T, Blann AD, Briët E, Vandenbroucke J, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152–155 Gill JC, Endress-Brooks J, Bauer PJ, Marks WJ Jr., Montgomery RR. The effect of ABO blood groups on the diagnosis of von Willebrand disease. Blood. 1987;69:1691–1695 Caekebeke-Peerlinck KMJ, Koster T, Briët E. Bleeding time, blood groups and von Willebrand factor. Br. J. Haematol. 1989;73:217–220 Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N. Engl. J. Med. 1994;331:1601–1606 Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N. Engl. J.Med. 1996;335:701–707 European Consensus Statement. Prevention of venous thromboembolism. Int. Angiol. 1992;11:151–159 Sikorski JM, Hampson WG, Staddon GE. The natural history and aetiology of deep vein thrombosis after hip replacement. J Bone Joint Surg. 1981;63-B:171–177 Nowak-Gottl U, Schaudin E, Hoffmann C, Eckhoff-Donovan S, Merthes N. Intraoperative clotting factor dilution and activated hemostasis in children with Ewinǵs sarcoma or osteosarcoma: a prospective longitudinal study. Haematologica. 1995;80(4):311–317 Menges T, Rupp D, van Lessen A, Hempelmann G. Measures for reducing the use of homologous blood. Effects on blood coagulation during total endoprothesis. Anaesthesist. 1992;41(19):27–33 Utada K, Matayoshi I, Sumi C, Itaya M, Miyawasaki H, Ito M, Tamura H, Mitsukuji I. Aprotinin 2 million KIU reduces perioperative blood loss in patients undergoing primary total hip replacement. Masui. 1997;46(1):77–82 Murkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Wyile G. Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth. Analg. 1995;80(2):343–348